Oral boards prep hasn't appreciably changed in decades, so I built MockUro, an AI examiner that walks you through ~250 canonical urology cases in Socratic Q&A format, grades your free-form answers across key domains, and adapts your study plan to your weak spots 🧵

If a surgical timeout works in the OR, it has to work for the morning routine, right? Going to hang a "TIME OUT" sign from the garage ceiling so we can officially confirm the presence of lunches, socks, and swim goggles before departure. Wish me luck. 🚦

Enduring legacy from John and Diane Quale and Mark Schoenberg 20 years (!!!) ago, when @PCORI was still a gleam in our eye, @BladderCancerUS set the standard for centering patients to drive the field forward ❤️🙏 (🥺miss all my peeps #bcantt26!)

Patient panel at #BCANTT26 is always inspiring and what makes the think tank unique. Our work is personal.

Excited to kickoff #BCANTT26 with @BladderCancerUS ! Inspiring open remarks by BCAN CEO Meri-Margaret Deoudes, Co-founder Diane Zipursky Quale, and Meeting Chair @MaxKates and Co-Chair @Parminder1699 . Every year this meeting highlights fantastic progress in the fight against #bladdercancer and points the way to a more hopeful future for so many patients affected by it.

The clinical trialists creed: Hubris is the enemy of progress.

At an FDA symposium in May, I was asked to discuss the BCG shortage which continues unabated unlike in Canada or Europe. In this editorial, we outline the paradox of approving non-tice BCG combinations while not allowing alternative strains in the market auajournals.org/doi/abs/10.1…

We're proud to celebrate four exceptional physicians completing their fellowship training at the Brady Urological Institute! Your advanced expertise and unwavering dedication to urological care will transform countless lives. We're honored to have been part of your journey!

Congratulations to our graduating Chief Residents! We're incredibly proud to celebrate three outstanding physicians who have completed their residency at the Brady Urological Institute: Zhuo (Tony) Su, M.D. Logan Galansky, M.D. Lamont Wilkins, M.D.

Clinical & research aren't separate. High-volume oncologic surgery requires mastery of both technique & disease. Who gets a cystectomy? Which 2nd-line agent for BCG-unresponsive NMIBC? 6 cystectomies/month is the floor but not the ceiling —the constant strive for perfection is.

Thrilled to welcome @BenPockros to @brady_urology and our @SUO_YUO fellowship led by @SHPatelMD1. 🙌🙌🙌. @nirmishsingla @arvinkgeorge @allaf_mo

Women's #BladderCancer program addresses sex-specific gaps in care and research. @akfsurgeon @brady_urology joins @TiansterZhang @UTSWMedCenter to discuss the Women's Bladder Cancer Program at @sibleyonline, a multidisciplinary initiative integrating urology, medical oncology, gynecology, social work, and physical therapy with female-specific quality-of-life questionnaires. #WatchNow on UroToday > bit.ly/4t72gXv

Incredible Commitment to Cancer Research by @davidjtrone. Trone Family Division of Urologic Oncology will be a place to accelerate innovation and progress for cancer patients everywhere. giving.jhu.edu/story/brady-u…. @brady_urology

🎉 Big news at @brady_urology! Deeply grateful for a transformational gift to establish the Trone Family Division of Urologic Oncology under leadership of @MaxKates! Honored & Inspired by @davidjtrone to "move the needle towards better cancer outcomes" giving.jhu.edu/story/brady-u…

This effort lead by @DrAndrewKatims , former @UrologyMSK @SUO_YUO fellow now at @nymedcollege , first looked at 610 NMIBC patients treated with radical cystectomy without any intervening treatment after their pre-RC TURBT; across multiple NMIBC subsets (BCG-Naïve, BCG unresponsive, use of Narrow Band Imaging, etc) we found that ~20% of patients with CIS on pre-RC TURBT had no residual CIS within their cystectomy specimen & equally important was that ~50% without CIS on pre-RC TURBT had occult CIS within their cystectomy specimen. We then partnered with @MaxKates & @Sadra_Sepehri to look at a NMIBC cohort who had blue light TURBT before cystectomy without intervening treatment @HopkinsGBCI @brady_urology and found nearly identical results; ~20% eradication of CIS by TURBT alone & ~50% occult CIS on cystectomy n/3

(1/) A transformational $10 million gift from the Robert & Lynda Carter Altman Family Foundation, championed by actress, philanthropist, & devoted advocate Lynda Carter, has made possible the naming & advancement of the Robert Altman Division (RAD) of Minimally Invasive Surgery.

Big congrats our BCAN Quale Fellows. And thank you to all the reviewers in this incredibly competitive application cycle We are fortunate to be in a golden age of bladder cancer progress. Thrilling to see that we are able to recruit such talent to the field. @BladderCancerUS

Interesting thought experiment. If you take the 5% absolute difference in RFS, and instead give BCG +IO as reinduction after the 10% of all patients recur at 3mo, would you get same benefit of IO and limit toxicity/over treatment? @WesKassouf @UroDocAsh